Bortezomib in the front-line treatment of multiple myeloma.
about
Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome bindingMechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingNF-kappa B modulation is involved in celastrol induced human multiple myeloma cell apoptosisNatural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaBp21(WAF1/CIP1) upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis.MiR-200c regulates Noxa expression and sensitivity to proteasomal inhibitors.Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trialThe novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation.ITPI: Initial Transcription Process-Based Identification Method of Bioactive Components in Traditional Chinese Medicine Formula.Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.Extramedullary relapse of IgA-lambda myeloma after recent bortezomib therapy: a case report.Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.The Mechanistic Links Between Proteasome Activity, Aging and Age-related Diseases.Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance.The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings.MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.Synthesis and pharmacology of proteasome inhibitors.Hematological malignancies: role of miRNAs and their in silico aspects.Peptide-based proteasome inhibitors in anticancer drug design.Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.Advances in multiple myeloma therapy during two past decades.Inhibitors of the proteasome stimulate the epithelial sodium channel (ENaC) through SGK1 and mimic the effect of aldosterone.Tyropeptins, proteasome inhibitors produced by Kitasatospora sp. MK993-dF2.Incidence and prognostic value of recurrent chromosomal abnormalities in elderly patients with multiple myeloma.Inactivation of the mTORC1-eukaryotic translation initiation factor 4E pathway alters stress granule formation.The chemotherapeutic agent bortezomib induces the formation of stress granules.An NMR Study of the Bortezomib Degradation under Clinical Use Conditions.Cannabinoids synergize with carfilzomib, reducing multiple myeloma cells viability and migration.Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant.Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy.The Proteasome and Myeloma-Associated Bone Disease.An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation
P2860
Q27677425-234E1FFF-EF14-4742-9FF6-AECE3AEFA616Q28082335-60A208CF-4829-490C-B19E-43B57EB08BACQ28538133-6C8F1051-59DA-4333-86ED-5EFE186BDCA7Q33775541-CBB2B285-C66D-4FF7-84AB-FDDEA56BC1ABQ33921377-306BAF6B-2949-4B03-82D8-C65C5FC5571FQ34277271-5A728E45-DC52-4277-9E6A-795288CF58EDQ35125893-54455DAB-D925-4D50-8BFB-6022CE9B128DQ35551777-D5BD39D9-5CCD-4E2E-AAB8-B9007DBA15CFQ36536365-6E23F213-D6BD-4136-8C55-0540F4EC5F63Q36680889-5D51A424-D8D2-44E6-BF20-908704AE554CQ37327280-EF2EBA73-4D8D-46D4-8A48-AC90A905E5DEQ37403468-A7310EC1-647A-4E66-9FE6-D63954B18D8AQ37634067-4BF3675B-A01C-4EAC-AEAD-940F242E486EQ37645630-73B4254C-2735-4300-9460-C84ED6A8A372Q37723478-22E4DA80-B0C0-42C6-A2BD-0447417C4ED0Q37851944-88B3617D-C2FE-4C97-8207-7BA3B71577FEQ37898151-E3F6CCCE-599E-4E01-AF31-B46E730F8B59Q38026589-2ECB0C88-A50E-445A-A167-01EF7E2A3DC7Q38092777-E84FFDF3-9EDE-4A60-9A80-379E03826962Q38140001-F3DCE919-55B9-40D1-9418-3108BE1892C3Q38192572-62ECFD8F-93B5-49C3-AE0D-9495B5A092DAQ38202977-7C215B1D-7623-40D5-8AFF-6E6596689903Q38248293-913D1190-BE02-4A5D-BE5F-CA5353683C0EQ38598428-8A0B4EA8-2ADF-4E10-B6F8-3022E7A0B542Q39135493-F1B69E10-D69C-4848-9FD8-45EB3BA51437Q39303373-4A7F6248-D388-415C-B94B-AD87D5F93AC8Q40525689-0F534367-6401-47A6-840E-9B9B115919B6Q40647498-BEF993B3-28AC-47FB-96FC-8C8EFE3A7275Q42122185-BD0ECF4A-C4FE-457C-BBBF-8EE2922268E5Q42314593-FB8318CF-9684-4541-8E5C-DD0BFC52064EQ42879120-08F1DFD4-A8ED-4367-9D91-22603F7A9D27Q43083995-403F3AA7-9557-4F56-85E3-7E31B87DF26FQ44279549-9985A4BD-8717-464D-AF0C-8871D56CEAE7Q47696279-34847313-AB6A-466A-A8EB-CECB6E332214Q57904533-79FF9DBA-EDC9-450D-97A2-27E3EA83AB4D
P2860
Bortezomib in the front-line treatment of multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bortezomib in the front-line treatment of multiple myeloma.
@en
Bortezomib in the front-line treatment of multiple myeloma.
@nl
type
label
Bortezomib in the front-line treatment of multiple myeloma.
@en
Bortezomib in the front-line treatment of multiple myeloma.
@nl
prefLabel
Bortezomib in the front-line treatment of multiple myeloma.
@en
Bortezomib in the front-line treatment of multiple myeloma.
@nl
P2093
P2860
P1476
Bortezomib in the front-line treatment of multiple myeloma.
@en
P2093
Constantine Mitsiades
Irene Ghobrial
Nikhil Munshi
Robert Schlossman
Teru Hideshima
P2860
P304
P356
10.1586/14737140.8.7.1053
P577
2008-07-01T00:00:00Z